Skip to content
Comparison

Wegovy vs Saxenda

Wegovy and Saxenda are commonly compared for semaglutide vs liraglutide obesity outcomes. Wegovy is usually favored for greater average weight reduction and weekly dosing, while Saxenda is often preferred for first-generation obesity GLP-1 with long clinical history. This head-to-head analysis focuses on mechanism, trial outcomes, dosing context, evidence quality, regulatory status, and practical decision points for safer YMYL decision-making.

4.3(112 ratings)

Quick Answer

For semaglutide vs liraglutide obesity outcomes, the better choice depends on your primary endpoint. Wegovy is stronger when the priority is higher expected weight-loss outcomes. Saxenda is stronger when the priority is patients preferring or already stable on liraglutide. Use evidence grade, dose intensity, access constraints, and tolerability profile to match therapy to the patient profile rather than choosing by hype alone.

Head-to-Head Comparison

CriteriaWegovySaxenda
Primary mechanismGLP-1 receptor agonist (semaglutide 2.4 mg obesity formulation)Liraglutide 3.0 mg obesity formulation
Strongest clinical signal~15% mean body-weight loss in STEP program~5-8% average weight loss in SCALE studies
Typical dosing contextEscalation to 2.4 mg weeklyDaily escalation to 3.0 mg
AdministrationWeekly subcutaneous injectionDaily subcutaneous injection
Evidence quality gradeStrong obesity outcomes and cardiovascular event reductionStrong but lower-magnitude obesity efficacy vs newer options
Regulatory statusFDA-approved for chronic weight managementFDA-approved for chronic weight management
Side-effect burdenGI effects dose-dependent; discontinuation can lead to regainKnown GLP-1 GI profile with daily dosing burden
Cost/access contextHigh list price; coverage varies widelyHigh cost and variable obesity-coverage policy
Best candidate profileObesity treatment with strong trial-grade outcomesPatients preferring established first-generation GLP-1 pathways
Main limitationRequires full-dose escalation for maximal efficacyLower efficacy and daily adherence burden
Best use case in this comparisonhigher expected weight-loss outcomespatients preferring or already stable on liraglutide

When to Choose Each

Choose Wegovy

Best for higher expected weight-loss outcomes.

Choose Saxenda

Best for patients preferring or already stable on liraglutide.

Verdict

If the main goal is higher expected weight-loss outcomes, Wegovy is usually the better first-line choice. If the main goal is patients preferring or already stable on liraglutide, Saxenda is typically the better fit. Reassess outcomes at 8-16 weeks with objective metrics, then adjust only when response, safety, or adherence data justify it. In high-risk populations, physician-guided personalization matters more than any generic ranking.

References

  1. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) (2021) — PubMed
  2. Semaglutide and cardiovascular outcomes in patients with obesity (SELECT trial) (2023) — PubMed
  3. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5) (2022) — PubMed
  4. Oral semaglutide versus subcutaneous liraglutide in type 2 diabetes (PIONEER 4) (2019) — PubMed

Compare Telehealth Providers

Find the right provider for your peptide therapy needs

Hims & Hers

Most Popular
4.3

Starting at $199/mo

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

✓Large, established platform with strong physician network
✓Compounded semaglutide available where branded shortages exist
✓Easy async consult — no video call required
✗Does not offer a wide range of peptides beyond GLP-1s
✗Pricing is on the higher end for GLP-1 programs

Henry Meds

Most Peptides
4.2

Starting at $249/mo

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

✓Broadest peptide therapy menu of any major telehealth provider
✓Growth hormone peptides (sermorelin, ipamorelin, CJC-1295) available
✓Repair peptides including BPC-157 and TB-500
✗Higher starting price due to comprehensive programs
✗More complex onboarding including lab work requirements

Ro Body

Best Value
4.1

Starting at $149/mo

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

✓Competitive pricing starting at $149/mo
✓Dedicated health coach included in program
✓Strong clinical protocols with lab-work integration
✗Narrower peptide offering — GLP-1s only
✗Video consult required for initial visit

Calibrate

4.0

Starting at $199/mo

Calibrate is a metabolic health company offering a one-year GLP-1 program built around four pillars: food, sleep, exercise, and emotional health. Calibrate works with insurance to cover medication costs and provides extensive behavioral coaching alongside prescriptions.

✓Insurance navigation support for medication coverage
✓Evidence-based one-year program with structured milestones
✓Four-pillar lifestyle coaching (food, sleep, exercise, emotional health)
✗Annual program commitment required
✗Primarily focused on GLP-1s — no broader peptide therapy

Found

3.9

Starting at $129/mo

Found is a weight management telehealth platform that combines GLP-1 medications with behavioral coaching and a supportive community. Found emphasizes a whole-person approach, pairing pharmacological treatment with lifestyle intervention for sustainable results.

✓One of the more affordable monthly program fees
✓Strong community and peer support features
✓Certified health coaches with regular check-ins
✗Medication billed separately from program fee — total cost can be higher
✗Limited peptide variety beyond standard GLP-1s

Sponsored · We may earn a commission. Learn more · Updated February 2026

Hims & HersMost Popular

Hims & Hers is a leading telehealth platform offering physician-supervised GLP-1 weight loss programs including compounded semaglutide and tirzepatide. Board-certified providers, async or video consults, and medication shipped to your door.

From $199/moLearn More →
Henry MedsMost Peptides

Henry Meds is a telehealth provider specializing in hormone optimization and peptide therapy. Beyond GLP-1 weight loss, Henry Meds offers testosterone replacement therapy, growth hormone peptides, and other advanced hormonal protocols managed by licensed physicians.

From $249/moLearn More →
Ro BodyBest Value

Ro Body is a telehealth weight management program powered by GLP-1 medications. Ro connects patients with licensed providers who prescribe compounded semaglutide or branded GLP-1 therapies depending on eligibility, paired with behavioral coaching.

From $149/moLearn More →

Sponsored · Affiliate Disclosure

Frequently Asked Questions

Which has stronger evidence for semaglutide vs liraglutide obesity outcomes — Wegovy or Saxenda?
Wegovy is graded as strong obesity outcomes and cardiovascular event reduction evidence in this context, while Saxenda is graded as strong but lower-magnitude obesity efficacy vs newer options. In practice, strength depends on whether you prioritize higher expected weight-loss outcomes or patients preferring or already stable on liraglutide. Favor the option with endpoint data closest to your primary goal, and avoid extrapolating beyond studied populations.
Can Wegovy and Saxenda be combined or sequenced?
Sometimes, but only with clinician oversight. A common framework is to start with one agent, track objective response for 8-16 weeks, then switch or sequence if outcomes plateau or tolerability is poor. Combination protocols may increase both cost and adverse-effect complexity, so they should be justified by clear endpoint-based rationale.
What should be monitored before and during treatment?
Baseline assessment should include diagnosis confirmation, comorbidity risk, and contraindications. During therapy, monitor target outcomes (symptoms, body composition, labs), adverse effects, and adherence burden. For endocrine/metabolic strategies, periodic glucose, lipids, organ function, and indication-specific labs help keep risk proportional to expected benefit.

Explore next